Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company’s common stock to seven newly hired...
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company’s common stock to one newly hired employee...
Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...
First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger...
Barchart Research What to Expect from SDGR Earnings SDGR Generated May 4, 2026 Current Price $12.90 EPS Estimate $$-0.56 Consensus Rating Moderate Buy Average Move 3.70% Schrödinger's Software Transition...
Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in May: BofA Securities 2026 Healthcare...
Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast...
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2026, the company granted restricted stock units (RSUs) with respect to 4,253 shares of the company’s common stock to four newly hired...
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company’s common stock to one newly hired...
2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports...